Review/Advances in Neurological Therapeutics (2024). Motor neuron disease

Abstract

Motor neuron diseases (MND) are devastating neurodegenerative disorders that primarily affect motor neurons, including amyotrophic lateral sclerosis (ALS), spinal muscular atrophy (SMA), and spinal bulbar muscular atrophy (SBMA). In 2024, based on the results of the JETALS trial, ultrahigh–dose methylcobalamin therapy was approved in Japan for ALS. This review provides a comprehensive overview of the clinical advancements in MND research and summarizes key literature on therapeutic approaches from 2024.